Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. Kartush, Jane Schumacher, Rachna Shah, M. Patadia (2018)
Biologic Agents for the Treatment of Chronic Rhinosinusitis With Nasal PolypsAmerican Journal of Rhinology & Allergy, 33
R. McQueen, Danielle Sheehan, M. Whittington, J. Boven, Jonathan Campbell (2018)
Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic EvaluationsPharmacoEconomics, 36
Kristine Smith, A. Pulsipher, David Gabrielsen, J. Alt (2018)
Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future DirectionsAmerican Journal of Rhinology & Allergy, 32
S. Dusetzina, N. Keating, H. Huskamp (2019)
Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices.The New England journal of medicine
P. Gevaert, L. Calus, T. Zele, Katrien Blomme, N. Ruyck, W. Bauters, P. Hellings, G. Brusselle, D. Bacquer, P. Cauwenberge, C. Bachert (2012)
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma.The Journal of allergy and clinical immunology, 131 1
S. Grosse (2008)
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdExpert Review of Pharmacoeconomics & Outcomes Research, 8
Noriko Ogasawara, J. Poposki, Aiko Klingler, B. Tan, K. Hulse, W. Stevens, Anju Peters, L. Grammer, Kevin Welch, Stephanie Smith, D. Conley, Joseph Raviv, P. Soroosh, K. Takano, T. Himi, R. Kern, R. Schleimer, A. Kato (2019)
Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polypsMucosal immunology, 13
P. Gevaert, N. Bruaene, T. Cattaert, K. Steen, T. Zele, F. Acke, N. Ruyck, Katrien Blomme, A. Sousa, R. Marshall, C. Bachert (2011)
Rhinitis , sinusitis , and upper airway disease Mepolizumab , a humanized anti – IL-5 mAb , as a treatment option for severe nasal polyposis
C. Incorvaia, M. Mauro, E. Makrì, G. Leo, E. Ridolo (2018)
Two decades with omalizumab: what we still have to learnBiologics : Targets & Therapy, 12
S. Grosse, T. Do, M. Vu, L. Feng, J. Berry, G. Sawicki (2018)
Healthcare expenditures for privately insured US patients with cystic fibrosis, 2010‐2016Pediatric Pulmonology, 53
M. Castro, J. Corren, I. Pavord, J. Maspero, S. Wenzel, K. Rabe, W. Busse, L. Ford, L. Sher, M. Fitzgerald, C. Katelaris, Y. Tohda, Bingzhi Zhang, H. Staudinger, G. Pirozzi, N. Amin, M. Ruddy, B. Akinlade, A. Khan, J. Chao, R. Martinčová, N. Graham, J. Hamilton, B. Swanson, N. Stahl, G. Yancopoulos, A. Teper (2018)
Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled AsthmaThe New England Journal of Medicine, 378
George Scangas, A. Remenschneider, Brooke Su, M. Shrime, R. Metson (2017)
Cost utility analysis of endoscopic sinus surgery for chronic rhinosinusitis with and without nasal polyposisThe Laryngoscope, 127
Minal Patel, V. Press, L. Gerald, Teresa Barnes, K. Blake, L. Brown, R. Costello, C. Crim, M. Forshag, A. Gershon, C. Goss, M. Han, Todd Lee, S. Sweet, J. Gerald (2018)
Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease. An Official American Thoracic Society Policy StatementAmerican Journal of Respiratory and Critical Care Medicine, 198
C. Bachert, Joseph Han, M. Desrosiers, P. Hellings, N. Amin, Stella Lee, J. Mullol, L. Greos, J. Bosso, T. Laidlaw, A. Cervin, J. Maspero, C. Hopkins, H. Olze, G. Canonica, P. Paggiaro, Seong-Hwan Cho, W. Fokkens, S. Fujieda, Mei Zhang, Xin Lu, C. Fan, Steven Draikiwicz, S. Kamat, A. Khan, G. Pirozzi, N. Patel, N. Graham, M. Ruddy, H. Staudinger, D. Weinreich, N. Stahl, G. Yancopoulos, L. Mannent (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 394
Lei Ren, N. Zhang, Luo Zhang, C. Bachert (2019)
Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the artThe World Allergy Organization Journal, 12
Sarah Faiz, J. Giovannelli, C. Podevin, M. Jachiet, J. Bouaziz, Z. Reguiai, A. Nosbaum, A. Lasek, M. Bouedec, A. Thanh, N. Raison-Peyron, F. Tétart, A. Duval-Modeste, L. Miséry, F. Aubin, A. Dompmartin, C. Morice, C. Droitcourt, A. Soria, J. Arnault, J. Delaunay, E. Mahé, M. Richard, A. Schoeffler, J. Lacour, E. Bégon, A. Walter-Lepage, A. Dillies, S. Rappelle-Duruy, S. Barete, N. Bellon, N. Bénéton, A. Valois, S. Barbarot, Julien Sénéchal, D. Staumont-Sallé (2019)
Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort.Journal of the American Academy of Dermatology, 81 1
R. Orlandi, T. Kingdom, P. Hwang (2016)
International Consensus Statement on Allergy and Rhinology: Rhinosinusitis Executive SummaryInternational Forum of Allergy & Rhinology, 6
C. Bachert, P. Gevaert, P. Hellings (2017)
Biotherapeutics in Chronic Rhinosinusitis with and without Nasal Polyps.The journal of allergy and clinical immunology. In practice, 5 6
(2018)
Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation
C. Iribarren, Abdelkader Rahmaoui, A. Long, S. Szefler, Mary Bradley, G. Carrigan, M. Eisner, Hubert Chen, T. Omachi, M. Farkouh, K. Rothman (2017)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthmaThe Journal of Allergy and Clinical Immunology, 139
H. Bauchner (2019)
Rationing of Health Care in the United States: An Inevitable Consequence of Increasing Health Care Costs.JAMA
C. Codispoti, Mahboobeh Mahadavinia (2019)
A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
C. Bachert, A. Sousa, V. Lund, G. Scadding, P. Gevaert, S. Nasser, S. Durham, M. Cornet, H. Kariyawasam, J. Gilbert, D. Austin, A. Maxwell, R. Marshall, W. Fokkens (2017)
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trialThe Journal of Allergy and Clinical Immunology, 140
W. Anderson, S. Szefler (2019)
Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 122 4
L. Rudmik, Z. Soler, J. Mace, R. Schlosser, Timothy Smith (2015)
Economic evaluation of endoscopic sinus surgery versus continued medical therapy for refractory chronic rhinosinusitisThe Laryngoscope, 125
J. Lam, J. Hay, J. Salcedo, N. Kenyon (2018)
A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthmaJournal of Asthma, 56
P. Vadagam, K. Kamal, Jordan Covvey, V. Giannetti, K. Mukherjee (2018)
Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic FibrosisJournal of Managed Care & Specialty Pharmacy, 24
George Scangas, A. Remenschneider, Brooke Su, M. Shrime, R. Metson (2017)
The impact of asthma on the cost effectiveness of surgery for chronic rhinosinusitis with nasal polypsInternational Forum of Allergy & Rhinology, 7
T. Numata, K. Nakayama, H. Utsumi, Kenji Kobayashi, Haruhiko Yanagisawa, Mitsuo Hashimoto, S. Minagawa, Takeo Ishikawa, Hiromichi Hara, J. Araya, K. Kuwano (2019)
Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitisBMC Pulmonary Medicine, 19
D. Fiorentino, V. Ho, M. Lebwohl, L. Leite, L. Hopkins, C. Galindo, K. Goyal, W. Langholff, S. Fakharzadeh, B. Srivastava, R. Langley (2017)
Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment RegistryJournal of the American Academy of Dermatology, 77
L. Rudmik (2017)
Economics of Chronic RhinosinusitisCurrent Allergy and Asthma Reports, 17
M. Whittington, R. McQueen, Daniel Ollendorf, Jeffrey Tice, Richard Chapman, Steven Pearson, Jonathan Campbell (2017)
Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 118 2
A. Long, Abdelkader Rahmaoui, K. Rothman, E. Guinan, M. Eisner, Mary Bradley, C. Iribarren, Hubert Chen, G. Carrigan, K. Rosen, S. Szefler (2014)
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab.The Journal of allergy and clinical immunology, 134 3
(2019)
Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: to biologic or not to biologic? Ann Allergy Asthma Immunol
W. Fokkens, V. Lund, C. Hopkins, P. Hellings, R. Kern, S. Reitsma, S. Toppila-Salmi, M. Bernal-Sprekelsen, J. Mullol, I. Alobid, W. Anselmo-Lima, C. Bachert, F. Baroody, C. Buchwald, A. Cervin, N. Cohen, J. Constantinidis, L. Gabory, M. Desrosiers, Z. Diamant, R. Douglas, P. Gevaert, A. Hafner, R. Harvey, G. Joos, L. Kalogjera, A. Knill, J. Kocks, B. Landis, J. Limpens, S. Lebeer, O. Lourenço, P. Matricardi, C. Meço, L. Mahony, C. Philpott, D. Ryan, R. Schlosser, B. Senior, T. Smith, T. Teeling, P. Tomazic, D. Wang, D. Wang, L. Zhang, A. Agius, C. Ahlstrom-Emanuelsson, R. Alabri, S. Albu, S. Alhabash, A. Aleksić, M. Aloulah, M. Al-Qudah, S. Alsaleh, M. Baban, T. Baudoin, T. Balvers, T. Battaglia, J. Bedoya, A. Beule, K. Bofares, I. Braverman, E. Brożek-Mądry, B. Richard, C. Callejas, S. Carrie, L. Caulley, D. Chussi, E. Corso, A. Coste, L. Devyani, U. Hadi, A. Elfarouk, P. Eloy, S. Farrokhi, G. Felisati, M. Ferrari, R. Fishchuk, W. Grayson, P. Gonçalves, B. Grdinić, V. Grgić, A. Hamizan, J. Heinichen, Samar Husain, T. Ping, J. Ivaška, F. Jakimovska, L. Jovančević, E. Kakande, R. Kamel, S. Karpischenko, H. Kariyawasam, A. Kjeldsen, L. Klimek, S. Kim, J. Letort, A. Lopatin, A. Mahdjoubi, J. Netkovski, D. Tshipukane, A. Obando-Valverde, M. Okano, M. Onerci, Y. Ong, R. Orlandi, K. Ouennoughy, M. Ozkan, A. Perić, J. Plzák, E. Prokopakis, N. Prepageran, A. Psaltis, B. Pugin, M. Raftopulos, P. Rombaux, S. Sahtout, C. Sarafoleanu, K. Searyoh, C. Rhee, J. Shi, M. Shkoukani, A. Shukuryan, M. Sičák, D. Smyth, K. Snidvongs, T. Košak, P. Stjarne (2020)
European Position Paper on Rhinosinusitis and Nasal Polyps 2020.Rhinology, 58 Suppl S29
Zuzhen Ou, Chao Chen, Aijun Chen, Yaowei Yang, Weikang Zhou (2018)
Adverse events of Dupilumab in adults with moderate‐to‐severe atopic dermatitis: A meta‐analysis☆International Immunopharmacology, 54
W. Stevens (2019)
A new treatment for chronic rhinosinusitis with nasal polypsThe Lancet, 394
Purpose of ReviewChronic rhinosinusitis with nasal polyps (CRSwNP) is a highly prevalent disease that results in significant healthcare-related costs as well as costs to society with lost productivity and time. Unfortunately, a significant percentage of patients who suffer with this disease will not find relief from current standard of care medications and surgery. With ongoing efforts to understand the pathophysiology of CRSwNP has come the introduction of monoclonal antibodies, or “biologics,” targeting specific elements of the inflammatory pathway in CRSwNP. Despite efficacy, these come at significant cost and, to date, no studies on the cost-efficacy of these biologics in CRSwNP have been published.Recent FindingsMultiple studies have now demonstrated efficacy for biologics in the treatment of CRSwNP as a primary indication. However, the gains in quality of life and objective measures, while consistent, are small and, arguably, the clinical significance is still unclear. In addition, the high cost of these medications may be hard to justify when evaluated in cost-efficacy studies against standard of care therapy in CRSwNP. Furthermore, while the current literature is most robust in showing the benefit of the biologics in asthma, it does not fully support cost-efficacy for biologics.SummaryThis review evaluates the current literature regarding efficacy of monoclonal antibodies for the treatment of CRSwNP and considers this efficacy in light of the cost implications to individuals and society.
Current Allergy and Asthma Reports – Springer Journals
Published: Apr 22, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.